Temedica has extended its Series B Round, adding €25 million to bring the Series B total to €42 million for this German startup.
Temedica originally focused on apps spinning up Pelvina, a pelvic floor training app for women and Mineo, a back training app, amongst others. The company has now pivoted to focus on data and personalized medicine.
This pivot, bolstered by their ‘Permea’ platform, appealed to MIG Capital who led the Series B extension. They note that “the newly developed real-world insights platform Permea provides pharmaceutical companies with a deep understanding of patients and their care in the real world, outside of clinical trials. Access to this unique 360° understanding of care realities has the potential to revolutionize our healthcare system as we know it.”
Click here to read the original news article.